Citadel Advisors’s Amryt Pharma AMYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-41,280
Closed -$301K – 15997
2022
Q4
$301K Sell
41,280
-23,768
-37% -$168K ﹤0.01% 9315
2022
Q3
$450K Sell
65,048
-26,447
-29% -$197K ﹤0.01% 8701
2022
Q2
$640K Buy
91,495
+48,085
+111% +$375K ﹤0.01% 8090
2022
Q1
$359K Sell
43,410
-529
-1% -$4.77K ﹤0.01% 10174
2021
Q4
$475K Buy
43,939
+32,318
+278% +$349K ﹤0.01% 9827
2021
Q3
$141K Buy
11,621
+491
+4% +$5.54K ﹤0.01% 12451
2021
Q2
$135K Buy
+11,130
New +$138K ﹤0.01% 12619

Other funds holding AMYT

Citadel Advisors's AMYT Position: Q1 2023 in Review

Citadel Advisors sold out of Amryt Pharma (AMYT) in Q1 2023, closing a stake of 41,280 shares — an estimated $301K sold.

Citadel Advisors first reported a position in AMYT in Q2 2021 and held it in 7 quarters. The position peaked at $640K in Q2 2022. 79 funds tracked by Wall St. Rank hold AMYT as of Q1 2023.

  • Citadel Advisors reported no remaining Amryt Pharma position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 41,280 Amryt Pharma shares in Q1 2023, an estimated $301K.
  • Citadel Advisors first reported a position in Amryt Pharma in Q2 2021 and held it in 7 quarters.
  • Citadel Advisors's Amryt Pharma position peaked at $640K in Q2 2022.
  • 79 funds tracked by Wall St. Rank held Amryt Pharma as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.